Clinical trials: Atherosclerosis
Common Iliac Artery Occlusive Disease, External Iliac Artery Occlusive Disease
Evaluation of the GORE® VIABAHN® BALLOON EXPANDABLE ENDOPROSTHESIS (VIABAHN BX)
The primary objective of the VBX13-05 clinical study is to evaluate the safety and efficacy of VIABAHN BX for the treatment of arterial occlusive disease in patients with de novo or restenotic lesions in the common and/or…
- Conditions
- Common Iliac Artery Occlusive Disease, External Iliac Artery Occlusive Disease, Peripheral Arterial Disease
- Trial name
- NCT01961167
- Testing
- Stenting of common and/or external iliacs
- Where
- New Zealand
- Volunteers
- 27 people
- Sponsor
- W.L.Gore & Associates
Peripheral Arterial Disease, Peripheral Artery Disease
Implementation of Telemedicine for Patient With Lower Extremity Wounds
The objective of this study is to determine if patients with lower extremity wounds in rural communities who undergo specialty referral through telemedicine have expedited care compared to patients who are treated through…
- Conditions
- Peripheral Arterial Disease, Peripheral Artery Disease, Peripheral Vascular Diseases, Diabetic Foot
- Trial name
- NCT04440839
- Testing
- Telemedicine specialty consultation
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- University of California, Davis
Coronary Artery Disease, Type 2 Diabetes Mellitus
Direct Renin Inhibition Effects on Atherosclerotic Biomarkers
The investigators aim to assess if a new blood pressure medication, aliskiren, reduces various biomarkers of heart disease found in the blood in patients with a history of both heart disease and type 2 diabetes.
- Trial name
- NCT00818779
- Testing
- Aliskiren, Amlodipine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Texas Tech University Health Sciences Center
Peripheral Artery Disease, Type 2 Diabetes
Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes
The hypothesis being that both aspirin-ticagrelor and ticagrelor monotherapy will be superior to aspirin monotherapy in the reduction of whole blood viscosity at the end of each 4 week treatment period.
- Trial name
- NCT02325466
- Testing
- Aspirin, Ticagrelor
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Peripheral Arterial Disease
Evaluation of the Pantheris Atherectomy System
A non-randomized, prospective, global clinical trial of the Avinger Pantheris System, an atherectomy device that provides directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque in diseased…
- Trial name
- VISION (NCT01937351)
- Testing
- Pantheris System
- Where
- 21 sites in United States, Germany
- Volunteers
- 162 people
- Sponsor
- Avinger, Inc.
Adverse Effect, Atherosclerosis, Coronary
Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease
Pioglitazone, a medication of thiazolidinedione group, is capable of triggering the peroxisome proliferator-activated receptors (PPAR-γ).
- Conditions
- Adverse Effect, Atherosclerosis, Coronary, Insulin Resistance Syndrome
- Trial name
- EFFORT (NCT03011775)
- Testing
- Pioglitazone 15 mg Tablet, Isosorbide Dinitrate 10Mg Tablet, Acetylsalicylic Acid 75Mg Tablet
- Where
- Ukraine
- Volunteers
- 43 people
- Sponsor
- Ukrainian Medical Stomatological Academy
Atherosclerotic Cardiovascular Disease
A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease
This study looks at how well a new medicine, NNC0385-0434, works to lower blood cholesterol levels. Participants will either get NNC0385-0434 as a tablet (a potential new medicine), or placebo as a tablet (a dummy medicine that…
- Trial name
- NCT04992065
- Testing
- NNC0385-0434 A 15 mg, NNC0385-0434 A 40 mg, NNC0385-0434 A 100 mg
- Where
- 44 sites in United States, Belgium and 5 more
- Volunteers
- 267 people
- Sponsor
- Novo Nordisk A/S
Peripheral Arterial Disease
Exercise and Weight Loss in PAD
This study is designed to examine the added benefits of weight loss to an exercise program in older obese Veterans with peripheral arterial disease.
- Trial name
- Action3 (NCT02607033)
- Testing
- Exercise, Weight Loss
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- VA Office of Research and Development
Peripheral Arterial Disease
Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities
The goal of this study is to evaluate whether supervised treadmill exercise combined with ranolazine 1000 mg twice daily provides an incremental benefit in absolute walking distance over supervised exercise alone in patients with…
- Trial name
- STERILE (NCT00914316)
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Corewell Health East
Vascular Inflammation, Atherosclerotic Cardiovascular Disease
Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study
Vascular inflammation, a central feature of atherosclerosis, participates in the initiation, perpetuation and instability of plaques.
- Trial name
- CIRT (NCT02576067)
- Testing
- Low dose methotrexate
- Where
- 3 sites in United States, Canada
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Critical Limb Ischemia
Safety and Efficacy of Autologous Bone Marrow Mononuclear Cells in Patients With Severe Critical Limb Ischemia
The purpose of this study is to evaluate the safety and efficacy of the concentrated autologous bone marrow derived stem cells for the treatment of Critical Limb Ischemia patients.
- Trial name
- NCT01472289
- Testing
- Autologous Bone Marrow Mononuclear cells (BMMNCs)
- Where
- India
- Volunteers
- 17 people
- Sponsor
- TotipotentSC Scientific Product Pvt. Ltd.
Coronary Artery Disease, Carotid Artery Disease
Assessment Of Vascular Health After Niacin Therapy (AVANT)
This study is looking to see if niacin will lessen atherosclerotic plaque inflammation and favorably affect circulating levels of endothelial progenitor cells and microparticles in people with atherosclerotic disease on chronic…
- Conditions
- Coronary Artery Disease, Carotid Artery Disease, Peripheral Artery Disease
- Trial name
- AVANT (NCT02003638)
- Testing
- Niacin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Pennsylvania
Peripheral Arterial Disease, Vascular Surgery
Remote Ischemic Preconditioning Prior to Vascular Surgery
The investigators have previously shown that elective vascular surgery is a high-risk operation with an anticipated risk of either death or heart attack of 15%.
- Trial name
- CRIPES (NCT01558596)
- Testing
- Preconditioning, Control
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- VA Office of Research and Development
Peripheral Arterial Disease
DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases
This study is an intra-individual comparison of DOTAREM®-enhanced MRA and GADOVIST®-enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases.
- Trial name
- NCT00955617
- Testing
- Contrast-enhanced MRA - Imaging examination
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Guerbet
Peripheral Arterial Disease (PAD)
Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)
The purpose of this study is to compare the difference between two magnetic resonance imaging (MRI) techniques for visualizing arteries.
- Trial name
- NCT00707876
- Testing
- ferumoxytol
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Coronary Artery Disease Risk High
FITT Exercise Counseling With Interactive Accelerometry and Physical Activity in Adolescents at Increased Risk of Early Cardiovascular Disease: A Pilot Study
This pilot study seeks to compare the change in energy expenditure and fitness levels of patients seen in the Children's Hospital Preventive Cardiology program receiving standard of care provider exercise counseling to similar…
- Trial name
- NCT01394705
- Testing
- BodyMedia
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Peripheral Artery Disease
The Pathway PVD Study for Percutaneous Peripheral Vascular Interventions
The Pathway PV Atherectomy System is a rotating, aspirating, expandable catheter for active removal of atherosclerotic debris and thrombus in peripheral vasculature.
- Trial name
- NCT00676494
- Testing
- Pathway PV Atherectomy System
- Volunteers
- 172 people
- Sponsor
- Pathway Medical Technologies Inc.
Diabetes Mellitus, Postprandial Lipemia
Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes
Sitagliptin is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-4), and has been shown to reduce fasting and postprandial glucose levels in patients with type 2 diabetes mainly through incretin hormone-mediated…
- Trial name
- NCT00660075
- Testing
- Sitagliptin
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Laval University
Dyslipidemias, High Cholesterol
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of…
- Conditions
- Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia
- Trial name
- BROADWAY (NCT05142722)
- Testing
- Obicetrapib
- Where
- 181 sites in United States, China and 6 more
- Volunteers
- 2,530 people
- Sponsor
- NewAmsterdam Pharma
Atherosclerosis of Native Arteries of the Extremities
Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project
To determine whether the Boston Scientific nitinol drug-eluting stent shows acceptable performance at 9 months when treating Superficial Femoral (SFA) and/or Proximal Popliteal Artery (PPA) lesions.
- Trial name
- MAJESTIC (NCT01820637)
- Testing
- The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)
- Where
- 13 sites in Australia, Austria and 3 more
- Volunteers
- 57 people
- Sponsor
- Boston Scientific Corporation